Trends in the incidence rate of genitourinary system cancers in Turkey: 2004-2015.


Journal

Turkish journal of urology
ISSN: 2149-3235
Titre abrégé: Turk J Urol
Pays: Turkey
ID NLM: 101643563

Informations de publication

Date de publication:
05 2020
Historique:
received: 14 01 2020
accepted: 26 02 2020
entrez: 14 5 2020
pubmed: 14 5 2020
medline: 14 5 2020
Statut: epublish

Résumé

To analyze age-standardized urological cancer incidence rates in Turkey during the last twelve years based on the available published data (2004-2015). Cancer data were obtained from the reports of Turkish Directorate of Public Health Cancer Department for 2004-2015. A trend analysis was conducted using the joinpoint regression analysis to observe the change in the trends over time. The average annual percentage of change, annual percent change, and the corresponding 95% confidence interval were calculated. Throughout the observed period, cancer incidence rates in men significantly increased by 3.04%, 4.70%, 4.03%, and 2.97% for all the genital organs, kidney, testis, and prostate, respectively. A significant increase of 3.11% and 1.91% was observed for the urinary system organs and bladder, respectively, of women during the same period. The increase in the incidence rate of urinary system cancers was more prominent than that of all cancers types in general. The total incidence rate of urinary system cancers (bladder and kidney) tends to increase more in women than in men. While there was no cancer with decreased incidence during the entire study period, similar decreases in some urogenital cancer types tended to occur during the second trend period.

Identifiants

pubmed: 32401704
pii: tud.2020.20008
doi: 10.5152/tud.2020.20008
pmc: PMC7219971
doi:

Types de publication

Journal Article

Langues

eng

Pagination

196-205

Références

J Natl Cancer Inst. 2010 May 5;102(9):605-13
pubmed: 20413742
Lancet. 2014 Dec 6;384(9959):2027-35
pubmed: 25108889
J Natl Cancer Inst. 2012 Jan 18;104(2):125-32
pubmed: 22228146
J Med Screen. 2014 Mar;21(1):24-9
pubmed: 24446330
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
Int J Cancer. 1999 Mar 15;80(6):827-41
pubmed: 10074914
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
pubmed: 15761078
Eur Urol. 2012 Jun;61(6):1079-92
pubmed: 22424666
Lancet Oncol. 2001 Sep;2(9):533-43
pubmed: 11905707
Stat Med. 2009 Dec 20;28(29):3670-82
pubmed: 19856324
Jpn J Clin Oncol. 2011 Jan;41(1):10-6
pubmed: 20558464
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Eur Rev Med Pharmacol Sci. 2015;19(5):805-12
pubmed: 25807434
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Turk J Urol. 2015 Dec;41(4):215-20
pubmed: 26623151

Auteurs

Pakize Yiğit (P)

Department of Medical Statistics and Medical Informatics, İstanbul Medipol University School of Medicine, İstanbul, Turkey.

Ömer Ataç (Ö)

Department of Public Health, İstanbul Medipol University School of Medicine, İstanbul, Turkey.

Sabahattin Aydın (S)

Department of Urology, İstanbul Medipol University School of Medicine, İstanbul, Turkey.

Classifications MeSH